KDR and gastric cancer: Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2), which functions as antiangiogenesis and has been recommended as a third-line treatment for metastatic gastric cancer patients.[7] So far, there is no literature reported using it for gastric cancer with high level of serum AFP.